Asandeutertinib vs Rilertinib (SH-1028)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline

Asandeutertinib

Marketed by TYK Medicines, Inc.

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Weak signal

NCT05146219 · Phase 2 · completed

The study treated 29 participants in a single arm without randomization, blinding, or a control group. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: December 2027 · NCT06672068 (registry estimate)

Reported efficacy

Intracranial Overall Response Rate (iORR) (13 months.); Extracranial Overall Response Rate (eORR) (13 months.): Confirmed investigator-assessed intracranial ORR 93.1% (95% CI: 77.2%-99.2%) in 29 patients at 160 mg once daily; median PFS 13.5 months (not_applicable)

Result source: NCT05146219

Rilertinib (SH-1028)

Marketed by Nanjing Sanhome Pharmaceutical

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Reliable signal

NCT04239833 · Phase 3 · status unknown

In this randomized, double-blind, active-controlled Phase 3 trial in patients with EGFR-mutated non-small-cell lung cancer, SH-1028 significantly extended progression-free survival compared with gefitinib, the standard EGFR-targeted therapy (median 19.3 months vs 9.8 months).

Next expected readout: February 2028 · NCT06080776 (registry estimate)

Reported efficacy

Median Progression Free Survival (PFS) (At baseline and every 6 weeks relative to randomisation until progression,up to 24 months.): Median PFS: 19.3 months (rilertinib/SH-1028) vs 9.8 months (gefitinib), HR 0.46, P<0.0001 -- primary endpoint met. (met)

Result source: NCT04239833

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAsandeutertinibRilertinib (SH-1028)
PFS, median—Trial running · NCT05382728—Trial running · NCT06080776
OS, median—Trial running · NCT05382728—Trial running · NCT06080776
ORR—Trial running · NCT05382728—Trial running · NCT06080776
Duration of response, median—Trial running · NCT05382728—Trial running · NCT06080776

PFS, median

Asandeutertinib
—Trial running · NCT05382728
Rilertinib (SH-1028)
—Trial running · NCT06080776

OS, median

Asandeutertinib
—Trial running · NCT05382728
Rilertinib (SH-1028)
—Trial running · NCT06080776

ORR

Asandeutertinib
—Trial running · NCT05382728
Rilertinib (SH-1028)
—Trial running · NCT06080776

Duration of response, median

Asandeutertinib
—Trial running · NCT05382728
Rilertinib (SH-1028)
—Trial running · NCT06080776
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Asandeutertinib
Confirmed investigator-assessed intracranial ORR 93.1% (95% CI: 77.2%-99.2%) in 29 patients at 160 mg once daily; median PFS 13.5 months NCT05146219 · Phase 2 · design grade: weak · publication or press release
Rilertinib (SH-1028)
Median PFS: 19.3 months (rilertinib/SH-1028) vs 9.8 months (gefitinib), HR 0.46, P<0.0001 -- primary endpoint met. NCT04239833 · Phase 3 · design grade: strong · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Asandeutertinib's landscape · Rilertinib (SH-1028)'s landscape